CJC-1295: research guide — mechanism, studies & variants
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue that has become one of the more widely studied peptides in growth hormone biology. Initially developed to explore sustained GH secretion, it’s now a standard tool for researchers investigating the hypothalamic-pituitary-somatotropic axis. This guide covers the mechanism, the key variants, what published studies actually show, and where the research gaps remain.
What Is CJC-1295?
CJC-1295 is a modified 30-amino acid version of growth hormone-releasing hormone (GHRH), the 44-amino acid peptide produced by the hypothalamus that tells the anterior pituitary to release growth hormone. The modifications aren’t random — four amino acid substitutions at positions 2, 8, 15, and 27 were specifically chosen to resist enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), which normally breaks down native GHRH within minutes.
The result is a compound with a dramatically longer half-life than endogenous GHRH, making it useful for research requiring sustained GH stimulation rather than the brief pulses the body normally produces.
CJC-1295 With DAC vs Without DAC
This is where most of the confusion lives, so it’s worth being precise.
CJC-1295 Without DAC (Mod GRF 1-29)
Without the Drug Affinity Complex, CJC-1295 — sometimes called Modified GRF (1-29) or Mod GRF 1-29 — has a circulating half-life of roughly 30 minutes. It’s cleared relatively quickly, producing a more pulsatile GH stimulation pattern that resembles the body’s natural secretory rhythm. Most researchers using the no-DAC variant pair it with a growth hormone-releasing peptide (GHRP) like Ipamorelin to amplify the GH pulse.
CJC-1295 With DAC
The DAC modification adds a lysine residue linked to a reactive fatty acid chain (maleimidopropionic acid). Once injected, this chain forms a covalent bond with serum albumin, which has a circulating half-life of roughly 19 days. By hitchhiking on albumin, CJC-1295 with DAC achieves a functional half-life of 5.8–8.1 days.
The trade-off is straightforward: the DAC version produces sustained, elevated GH levels rather than discrete pulses. Whether pulsatile or continuous GH elevation is more desirable depends entirely on what you’re studying.
| Property | CJC-1295 No DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Half-life | ~30 minutes | 5.8–8.1 days |
| GH stimulation pattern | Pulsatile (mimics natural rhythm) | Sustained elevation |
| Albumin binding | No | Yes (covalent) |
| Typical research use | Often combined with GHRP | Standalone sustained GH studies |
| Dosing frequency in studies | Multiple times daily | Once or twice weekly |
Mechanism of Action
CJC-1295 binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. The receptor is a G-protein coupled receptor — when CJC-1295 binds, it activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). This activates protein kinase A (PKA), which triggers two things: increased transcription of the GH gene, and exocytosis of stored GH vesicles.
The downstream effects cascade through the liver, where GH stimulates production of IGF-1 (insulin-like growth factor 1). IGF-1 mediates most of the peripheral anabolic and metabolic effects attributed to GH signalling — muscle protein synthesis, bone growth, fat metabolism.
A few things worth noting about the mechanism:
- CJC-1295 acts upstream of GH — it stimulates the pituitary’s own GH-producing cells rather than replacing GH directly
- It preserves normal pituitary feedback mechanisms, including somatostatin-mediated inhibition
- At research concentrations, it doesn’t directly activate insulin or cortisol pathways — an important distinction from exogenous GH administration
- The GHRHR has relatively low expression density compared to other pituitary receptors, which may explain the dose-dependent ceiling effects observed in clinical studies
Key Studies
Teichman et al. (2006) — The Foundational Study
The most cited CJC-1295 study is Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006. This was two randomised, placebo-controlled, double-blind, ascending-dose trials conducted across two sites in healthy adults aged 21–61.
After a single injection of CJC-1295 (with DAC), mean plasma GH concentrations increased 2- to 10-fold for 6 days or more. Mean plasma IGF-1 levels increased 1.5- to 3-fold for 9–11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. The estimated half-life was 5.8–8.1 days, consistent with the albumin-binding mechanism.
No serious adverse reactions were reported. The authors concluded that subcutaneous CJC-1295 produced “sustained, dose-dependent increases in GH and IGF-I levels” and was “safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg.”
Alba et al. (2006) — Pulsatile GH Persistence
A companion study by Alba et al., also in the JCEM (2006), made an interesting finding: even during continuous CJC-1295 stimulation, pulsatile GH secretion persisted. This suggested that normal somatostatin feedback remained functional, which was reassuring — it meant CJC-1295 wasn’t overriding the body’s regulatory mechanisms. The GH pulses were amplified in both frequency and amplitude, but the overall secretory pattern remained recognisably physiological.
Body Composition Research
Published research has explored sustained GH elevation effects on body composition markers — lean mass and fat mass. The results align with known GH signalling effects: anabolic stimulus to muscle tissue and increased lipolysis. However, the body composition studies are smaller and less rigorously controlled than the pharmacokinetic work, so the data should be read with appropriate caution.
CJC-1295 and Ipamorelin Combination Research
The CJC-1295 (without DAC) plus Ipamorelin combination is probably the most commonly studied GHRH/GHRP pairing. The rationale is mechanistic: CJC-1295 activates the GHRH receptor pathway (via cAMP), while Ipamorelin activates the ghrelin/GHSR-1a pathway (via phospholipase C and intracellular calcium mobilisation). These are genuinely distinct signalling cascades converging on the same cell type.
Preclinical data in porcine models (Jorgensen et al., 2001) showed that co-administration of a GHRH analogue with a ghrelin-pathway agonist produced GH responses 2–4 times greater than either compound alone at equivalent doses. Research protocols using both compounds in combination consistently show IGF-1 elevation roughly 20–30% higher than either compound individually.
The appeal of Ipamorelin specifically (versus older GHRPs like GHRP-6 or GHRP-2) is its selectivity. Ipamorelin produces GH release without significantly affecting cortisol or prolactin, which makes for cleaner experimental conditions.
That said, published peer-reviewed trials demonstrating superior body composition or performance outcomes from the combination in healthy adults are still lacking. The synergy is well-established at the hormonal level; the clinical translation is still catching up.
| Study | Year | Key Finding |
|---|---|---|
| Teichman et al., JCEM | 2006 | Single CJC-1295 injection sustained GH elevation for 6+ days, IGF-1 for 9-11 days |
| Alba et al., JCEM | 2006 | Pulsatile GH secretion persists during continuous CJC-1295 stimulation |
| Jorgensen et al. | 2001 | GHRH + ghrelin pathway co-stimulation produced 2-4x GH response vs either alone |
Research Considerations
Purity Requirements
GHRH analogue research requires high-purity compounds — impurities confound variables and compromise data integrity. HPLC verification with a Certificate of Analysis is standard for research-grade peptide procurement. This isn’t a formality; contaminated peptide batches have derailed studies.
Storage
CJC-1295 is typically stored lyophilised (freeze-dried) for long-term stability. Reconstituted solutions should be refrigerated and used within standard peptide storage timeframes. Repeated freeze-thaw cycles degrade the compound.
Conclusion
CJC-1295 is a well-characterised tool for studying growth hormone biology. The pharmacokinetic data is solid, the mechanism is well understood, and the DAC/no-DAC distinction offers researchers genuine flexibility in experimental design. The combination with Ipamorelin adds another dimension, though the clinical evidence for that pairing still lags behind the mechanistic rationale.
The main limitation is that most published work focuses on hormonal endpoints — GH and IGF-1 levels — rather than functional outcomes. That’s where future research needs to go.
For researchers needing CJC-1295, Amino Research provides both variants (with and without DAC), verified to ≥98% purity by HPLC and mass spectrometry, with a Certificate of Analysis included with every order.
Related Reading
- BPC-157 in Musculoskeletal Research: Systematic Review
- RFK Jr., the FDA, and 14 Peptides: What the Regulatory Shift Means
- The Peptide Boom: Why the Market Is Doubling by 2033
- Epithalon: The Telomere Peptide with 40 Years of Research
- GLP-1 Peptides: Beyond Weight Loss — The Longevity Case